Compass Pathways Plc (CMPS) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$15.10

From 52W high+0.00%

Volume3.52M

Market cap$2.10B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$15.10

From 52W high

+0.00%

Volume

3.52M

Market cap

$2.10B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

P/E (TTM)

—

RSI (14)

58.7

MomentumView details →

1D Return

+1.27%

YTD Return

+115.88%

SummaryUpdated Jun 1, 2026

COMPASS Pathways plc (NASDAQ:CMPS) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in London, United Kingdom. The company went public in September 2020 and focuses exclusively on developing psilocybin-based therapies for mental health conditions. COMPASS represents one of the pioneering companies in the emerging field of psychedelic medicine, seeking to bring scientifically rigorous approaches to substances that were previously relegated to recreational or underground therapeutic use. The company's primary asset is COMP360, a proprietary psilocybin therapy currently in Phase III clinical trials for treatment-resistant depression.

Ask drillr about Compass Pathways Plc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

24.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−466.31%

ROA (TTM)

−78.12%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−8.66%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−33.91%

EBITDA YoY

—

MomentumView details →

1D Return

+1.27%

YTD Return

+115.88%

1Y Return

+204.00%

RSI (14)

58.7

vs 50D SMA

+12.60%

vs 200D SMA

+55.58%

Capital & dividendView details →

Debt/Equity

0.65x

Current Ratio

1.30x

Quick Ratio

1.30x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.88

EPS Surprise

−308.70%

Beats (12Q)

4/12

Next Q EPS Est

−$0.36

Avg Surprise (4Q)

−78.57%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−394.19M

Op. CF (TTM)

−161.14M

Next earningsNov 3, 2026 →

Latest newsMore news →

COMPASS Pathways plc reported its Q2 2026 and H1 2026 financial results, including a net loss of $253.8 million for Q2 2026 and $162.6 million for H1 2026, with cash position of $433 million at end of Q2 2026.47d ago

Similar companies

Pediatrix Medical Group, Inc.MD Select Medical Holdings CorporationSEM Addus HomeCare CorporationADUS Astrana Health, Inc.ASTH Jiangxi Rimag Group Co., Ltd.02522.HK Saint Bella Inc.02508.HK Find similar companies →

Latest newsMore news →